Canine Atopic Dermatitis Market to Grow with a CAGR of 9.90% through 2028
Increase in the number of pet owners and advancements
in veterinary medicine is expected to drive the Global Canine Atopic Dermatitis
Market growth in the forecast period, 2024-2028
According to TechSci Research report, “Canine
Atopic Dermatitis Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global Canine
Atopic Dermatitis Market stood at USD 995.60 million in 2022 and is anticipated
to grow with a CAGR of 9.90% in the forecast period, 2024-2028. This can be
attributed to growing veterinary care awareness. Pet owners are increasingly
recognizing the importance of regular veterinary care and seeking professional
advice on their pets' health. This increased awareness has led to earlier
diagnosis and better management of conditions like atopic dermatitis, further
driving the demand for associated treatments and solutions. Furthermore, the global nature of the canine atopic
dermatitis market encourages cross-border collaboration and research. Awareness
and collaboration between veterinarians, pharmaceutical companies, and pet
healthcare providers are expected to grow, furthering the development of
innovative treatments and diagnostic tools.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Canine Atopic Dermatitis Market”
The primary driving force behind this market is the
escalating instances of atopic dermatitis in dogs, which are exacerbated by
factors such as air pollution and allergens. The most frequently observed
symptoms linked to atopic dermatitis include itching, scratching, hair loss,
scaly skin, and unpleasant odors. Breeds particularly prone to this canine skin
condition encompass Golden Retrievers, German Shepherds, Labradors, and Pugs.
The swift industrialization seen in both developed and developing nations is
expected to further stimulate market expansion.
According to a report from the American College of
Veterinary Dermatology (ACVD), approximately 10% to 15% of dogs were afflicted
by canine atopic dermatitis in 2017. Although the exact cause of this ailment
remains not entirely understood, genetic abnormalities have been identified as
one of the principal contributing factors. According to a study published in
the American Journal Of Veterinary Research, in the UK, Golden Retrievers
exhibited a nearly 50% risk of developing canine atopic dermatitis due to geographic
variations, a factor likely to enhance revenue in the years to come.
The growing number of veterinary professionals stands
out as a significant factor spurring demand in this market. According to data
from the American Veterinary Medical Association, there were a total of 113,394
veterinary practitioners in the United States in 2018, compared to 110,531 in
2017. Moreover, the proliferation of veterinary hospitals and clinics is
further propelling market growth. Furthermore, the industry's key players are making
substantial investments in research and development, launching new products,
and maintaining a robust drug pipeline, all of which are expected to make
substantial contributions to market expansion. For example, Kindred
Biosciences, Inc. reportedly has four monoclonal antibodies for canine atopic
dermatitis in their pipeline, set to debut in the next five years. In 2016,
Zoetis introduced Cytopoint, a monoclonal antibody that achieved blockbuster
status in 2018. The increasing demand for pet insurance and the
growing concern among pet owners are expected to have a favorable impact on the
market in the years to come. Moreover, stringent regulations enforced by the
Food and Drug Administration (FDA) and other regulatory bodies to curtail the
off-label use of human drugs in animals are bolstering market growth.
The Global Canine Atopic Dermatitis Market is
segmented into product, mode of administration, distribution channel, regional
distribution, and company
Based on its product, Glucocorticoids emerged as the
dominant revenue generator in 2022 due to increased usage and lower costs.
Topical and oral forms of glucocorticoids were identified as the primary
treatment option for managing canine atopic dermatitis, with oral medications
like prednisone, prednisolone, and methylprednisolone being the preferred
choices for treating acute flares. These oral forms also boast minimal side
effects compared to other dosage methods.
Looking ahead, the Monoclonal Antibodies (MAbs)
segment is poised for significant growth during the forecast period. This
treatment approach is relatively new and has demonstrated high effectiveness.
Zoetis introduced its first MAb in 2016, administered every four to eight weeks
to provide immediate relief from itching. Furthermore, several MAbs are
currently undergoing clinical trials, with positive results expected in the
coming years.
Based on distribution channel, the retail sector
established its dominance in the market during 2022, primarily due to an
expanded availability of products. The emergence of retail pharmacy chains
plays a significant role in the distribution channel segment's market share.
The implementation of digitalized systems in retail pharmacies, aimed at
reducing prescription errors, is expected to drive revenue growth in the coming
years. Additionally, veterinarians have increasingly turned to general
pharmacies to fulfill prescriptions for medications not readily available in
veterinary pharmacies, further boosting market expansion.
The rising popularity of e-commerce channels stands as
a pivotal factor contributing to the attractiveness of the e-commerce segment
throughout the forecast period. The convenience of selecting from websites
offering a broad array of products along with comprehensive product
descriptions is fueling this growth. Furthermore, discounts available on
various e-commerce platforms and the growing consumer inclination towards
online purchasing are anticipated to propel revenue growth in this segment.
Major companies operating in Global Canine Atopic
Dermatitis Market are:
- Zoetis Inc
- Elanco Animal Health Inc
- Virbac SA
- Toray Industries Inc
- AB Science SA
- Boehringer Ingelheim GmbH
- Kindred Biosciences Inc
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“The future of the global canine atopic dermatitis
market promises to be characterized by innovation and a focus on improving the
lives of dogs affected by this condition. Personalized medicine, immunotherapy
advancements, targeted therapies, and holistic approaches are just a few of the
trends set to shape the market's growth. As the bond between humans and their
canine companions deepens, so does the dedication to enhancing the well-being
of dogs suffering from atopic dermatitis. The ongoing evolution of the market
will bring us closer to that goal,” said Mr. Karan Chechi, Research Director
with TechSci Research, a research-based management consulting firm.
“Canine Atopic Dermatitis Market By Product
(Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others), By Mode of
Administration (Topical, Oral, Injectable), By Distribution Channel (Veterinary
Hospitals/Clinics, Retail, E-commerce), By
Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Global Canine Atopic Dermatitis Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Canine Atopic Dermatitis Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com